Operating Margin: 30.06%
Is the operating margin high or low?
The operating margin of 30.06% is 44% above its 5-year average of 20.88%, near the high end of its 5-year range (2.36%–31.89%).
As of Sunday, June 28, 2026. 13.26% above its 12-month average of 26.54%.
GSK Operating Margin
Reported quarterly operating margin; no daily interpolation.
GSK Average Operating Margin Chart
GSK Current vs Average Operating Margin Chart
GSK Operating Margin Metrics
OPERATING MARGIN
30.06%
OPERATING MARGIN AVG TTM
26.54%
OPERATING MARGIN AVG 3Y
21.20%
OPERATING MARGIN AVG 5Y
20.88%
OPERATING MARGIN AVG 10Y
18.87%
OPERATING MARGIN AVG 15Y
20.55%
OPERATING MARGIN AVG 20Y
22.75%
CURRENT VS TTM AVG
+13.26%
CURRENT VS 3Y AVG
+41.80%
CURRENT VS 5Y AVG
+43.95%
CURRENT VS 10Y AVG
+59.28%
CURRENT VS 15Y AVG
+46.27%
CURRENT VS 20Y AVG
+32.09%
GSK Competitors' Operating Margin
| NAME | MARKET CAP | OPERATING MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GSK plc (GSK) | $105.20B | 30.06% | 26.54% | 21.20% | 20.88% |
| Medtronic plc (MDT)vs › | $103.66B | 17.78% | 17.77% | 17.25% | 17.00% |
| Bristol-Myers Squibb Company (BMY)vs › | $117.46B | 25.67% | 23.17% | 21.31% | 19.39% |
| McKesson Corporation (MCK)vs › | $89.39B | 1.58% | 1.41% | 1.42% | 1.37% |
| HCA Healthcare, Inc. (HCA)vs › | $86.89B | 15.67% | 15.38% | 15.15% | 15.20% |
| Elevance Health Inc. (ELV)vs › | $85.82B | 3.81% | 4.55% | 4.90% | 5.40% |
| Vertex Pharmaceuticals Incorporated (VRTX)vs › | $124.70B | 38.97% | 18.66% | 31.09% | 34.52% |
| Stryker Corporation (SYK)vs › | $127.39B | 21.34% | 20.93% | 20.75% | 21.02% |
| CVS Health Corp. (CVS)vs › | $133.13B | 1.46% | 2.43% | 2.79% | 3.48% |
| Cigna Corporation (CI)vs › | $74.81B | 3.42% | 3.56% | 4.04% | 4.30% |
Operating Efficiency
Gross Margin
72.7%
Operating Margin
30.1%
Operating Margin Formula & Definition
Operating Margin = Operating Income / Revenue
Operating margin is the percentage of revenue remaining after operating expenses, reflecting operating efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Operating Margin FAQ
- What is the operating margin for GSK plc (GSK)?
- The operating margin for GSK stock is 30.06%.
- Is GSK plc's operating margin high or low?
- The operating margin of 30.06% is 44% above its 5-year average of 20.88%, near the high end of its 5-year range (2.36%–31.89%).
- What is the TTM average operating margin for GSK plc (GSK)?
- The TTM average operating margin for GSK stock is 26.54%.
- What is the 3Y average operating margin for GSK plc (GSK)?
- The 3Y average operating margin for GSK stock is 21.20%.
- What is the 5Y average operating margin for GSK plc (GSK)?
- The 5Y average operating margin for GSK stock is 20.88%.
- What is the 10Y average operating margin for GSK plc (GSK)?
- The 10Y average operating margin for GSK stock is 18.87%.
- What is the 15Y average operating margin for GSK plc (GSK)?
- The 15Y average operating margin for GSK stock is 20.55%.
- What is the 20Y average operating margin for GSK plc (GSK)?
- The 20Y average operating margin for GSK stock is 22.75%.
GSK Operating Margin History
| DATE | OPERATING MARGIN |
|---|---|
| 2026-03-31 | 30.06% |
| 2025-12-31 | 17.48% |
| 2025-09-30 | 30.34% |
| 2025-06-30 | 25.33% |
| 2025-03-31 | 29.48% |
| 2024-12-31 | 8.57% |
| 2024-09-30 | 2.36% |
| 2024-06-30 | 20.88% |
| 2024-03-31 | 20.24% |
| 2023-12-31 | 7.12% |
| 2023-09-30 | 23.92% |
| 2023-06-30 | 29.83% |
| 2023-03-31 | 29.95% |
| 2022-12-31 | 25.33% |
| 2022-09-30 | 15.21% |
| 2022-06-30 | 15.60% |
| 2022-03-31 | 31.89% |
| 2021-12-31 | 9.39% |
| 2021-09-30 | 20.82% |
| 2021-06-30 | 21.84% |
| 2021-03-31 | 22.82% |
| 2020-12-31 | 12.14% |
| 2020-09-30 | 21.49% |
| 2020-06-30 | 37.38% |
| 2020-03-31 | 22.16% |
| 2019-12-31 | 21.37% |
| 2019-09-30 | 22.88% |
| 2019-06-30 | 19.00% |
| 2019-03-31 | 18.64% |
| 2018-12-31 | 18.96% |
| 2018-09-30 | 23.60% |
| 2018-06-30 | 10.66% |
| 2018-03-31 | 17.17% |
| 2017-12-31 | 6.70% |
| 2017-09-30 | 23.93% |
| 2017-06-30 | -0.27% |
| 2017-03-31 | 23.27% |
| 2016-12-31 | 7.84% |
| 2016-09-30 | 18.97% |
| 2016-06-30 | -2.31% |
| 2016-03-31 | 11.61% |
| 2015-12-31 | -4.04% |
| 2015-09-30 | 16.73% |
| 2015-06-30 | 5.69% |
| 2015-03-31 | 163.93% |
| 2014-12-31 | 11.17% |
| 2014-09-30 | 12.45% |
| 2014-06-30 | 20.45% |
| 2014-03-31 | 18.99% |
| 2013-12-31 | 35.35% |
| 2013-09-30 | 24.10% |
| 2013-06-30 | 21.73% |
| 2013-03-31 | 24.42% |
| 2012-12-31 | 28.52% |
| 2012-09-30 | 25.37% |
| 2012-06-30 | 26.51% |
| 2012-03-31 | 30.33% |
| 2011-12-31 | 26.93% |
| 2011-09-30 | 29.77% |
| 2011-06-30 | 26.46% |
| 2011-03-31 | 30.90% |
| 2010-12-31 | -4.45% |
| 2010-09-30 | 28.74% |
| 2010-06-30 | 0.73% |
| 2010-03-31 | 28.46% |
| 2009-12-31 | 30.23% |
| 2009-09-30 | 30.65% |
| 2009-06-30 | 32.53% |
| 2009-03-31 | 25.29% |
| 2008-12-31 | 22.89% |
| 2008-09-30 | 28.17% |
| 2008-06-30 | 33.01% |
| 2008-03-31 | 34.52% |
| 2007-12-31 | 63.24% |
| 2007-09-30 | 34.88% |
| 2007-06-30 | 34.00% |
| 2007-03-31 | 38.73% |
| 2006-12-31 | 28.53% |
| 2006-09-30 | 35.86% |
| 2006-06-30 | 32.88% |
| 2006-03-31 | 37.40% |
| 2005-12-31 | -82.63% |
| 2005-09-30 | 32.59% |
| 2005-06-30 | 32.61% |
| 2005-03-31 | 34.69% |
| 2004-12-31 | 29.15% |
| 2004-09-30 | 30.40% |
| 2004-06-30 | 30.68% |
| 2004-03-31 | 30.75% |
| 2003-12-31 | 21.37% |
| 2003-09-30 | 30.55% |
| 2003-06-30 | 35.16% |
| 2003-03-31 | 32.21% |
| 2002-12-31 | 23.80% |
| 2002-09-30 | 22.43% |
| 2002-06-30 | 30.30% |
About GSK plc
GSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical solutions. Until May 2022, the company was known as GlaxoSmithKline plc. Its primary objective is to prevent and treat illnesses by producing both vaccines and a comprehensive range of specialty and general medicines for markets across the United Kingdom, the United States, and internationally. The company's operations are organized into two key divisions: Commercial Operations and Total R&D. Its extensive vaccine portfolio includes immunizations against shingles, meningitis, respiratory syncytial virus (RSV), seasonal and pandemic influenza, and polio. Beyond preventative care, GSK provides diverse therapeutic products covering critical areas such as HIV, oncology, respiratory and immunology conditions, and other specialized medical fields. This also encompasses inhaled treatments for chronic respiratory ailments like asthma and chronic obstructive pulmonary disease (COPD), along with antibiotics for various infections. Innovation at GSK is frequently driven by strategic partnerships. Notable collaborations include an agreement with CureVac to advance mRNA-based influenza vaccines, and alliances with Wave Life Sciences and Elsie Biotechnologies focused on developing oligonucleotide platforms. Furthermore, GSK has established two distinct strategic collaborations with Relation to progress therapeutics for fibrotic diseases and osteoarthritis. The company is also engaged in a multi-target strategic alliance aimed at developing pioneering treatments for individuals suffering from Parkinson's disease, and a partnership with Flagship Pioneering to identify novel medicines and vaccines.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Luke Victor Miels